Connor Clark & Lunn Investment Management Ltd. Sells 27,540 Shares of AngioDynamics, Inc. $ANGO

Connor Clark & Lunn Investment Management Ltd. trimmed its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 5.7% during the second quarter, Holdings Channel reports. The firm owned 459,238 shares of the medical instruments supplier’s stock after selling 27,540 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in AngioDynamics were worth $4,556,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in ANGO. Armistice Capital LLC increased its holdings in AngioDynamics by 140.1% in the first quarter. Armistice Capital LLC now owns 2,094,000 shares of the medical instruments supplier’s stock worth $19,663,000 after purchasing an additional 1,222,000 shares in the last quarter. Nuveen LLC acquired a new stake in shares of AngioDynamics during the 1st quarter worth approximately $10,803,000. Bastion Asset Management Inc. bought a new stake in shares of AngioDynamics in the 1st quarter valued at $6,601,000. AIGH Capital Management LLC acquired a new position in shares of AngioDynamics during the 1st quarter valued at $4,455,000. Finally, Phocas Financial Corp. acquired a new position in shares of AngioDynamics during the 1st quarter valued at $3,177,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

Insider Activity at AngioDynamics

In related news, SVP Lawrence T. Weiss bought 10,000 shares of the company’s stock in a transaction dated Tuesday, October 21st. The shares were bought at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the completion of the acquisition, the senior vice president directly owned 93,597 shares of the company’s stock, valued at $1,105,380.57. This trade represents a 11.96% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO James C. Clemmer bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, October 9th. The shares were bought at an average cost of $11.15 per share, for a total transaction of $111,500.00. Following the transaction, the chief executive officer owned 882,529 shares of the company’s stock, valued at $9,840,198.35. The trade was a 1.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders bought 20,890 shares of company stock valued at $239,532. Company insiders own 6.00% of the company’s stock.

AngioDynamics Price Performance

Shares of NASDAQ ANGO opened at $12.30 on Friday. The company has a 50-day moving average price of $11.44 and a 200-day moving average price of $10.21. The stock has a market capitalization of $506.76 million, a P/E ratio of -15.77 and a beta of 0.74. AngioDynamics, Inc. has a 1 year low of $6.63 and a 1 year high of $13.50.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The company had revenue of $75.71 million for the quarter, compared to analyst estimates of $72.69 million. During the same quarter in the prior year, the business posted ($0.11) EPS. The firm’s revenue was up 12.1% compared to the same quarter last year. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. As a group, equities research analysts anticipate that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Wall Street Zen cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday, October 4th. Canaccord Genuity Group boosted their target price on AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $19.33.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.